LHDX - LHDX STOCK NEWS

Lucira Health announced it will report its first quarter 2022 financial results on May 12, 2022. A conference call will follow at 1:30 p.m. PT to discuss the results and corporate updates. Lucira specializes in innovative infectious disease test kits, offering lab-quality molecular testing in user-friendly, single-use kits. Their tests are utilized by major organizations like Salesforce and Amazon. The company is also developing new diagnostic tests for COVID-19 and Flu.

Lucira Health partners with USA Boxing as the official COVID-19 test provider for the 2022 season. For every test purchased, Lucira will donate $5 to USA Boxing, with a cap of $50,000. The partnership aims to ensure the safety of athletes, coaches, and staff during training and events.

Lucira's Check-It COVID-19 test kit, priced at $75, is the only FDA-authorized single-use molecular test for at-home use. Prominent organizations like the NHL and Amazon use Lucira tests, reinforcing their credibility in testing.

Lucira Health, Inc. (Nasdaq: LHDX) announced the grant of 20,825 restricted stock units (RSUs) to three new employees as part of their 2022 Inducement Plan on April 6, 2022. The RSUs aim to incentivize the new hires, vesting over four years, with 25% of shares vesting after one year and the remainder vesting quarterly. Lucira is focused on innovative infectious disease test kits, including the Lucira™ Check-It COVID-19 Test Kit, which provides results within 30 minutes.

Lucira Health (LHDX) has donated 2,000 at-home COVID-19 tests to Tonga's Red Cross Society following the Hunga Tonga-Hunga Ha'apai volcanic eruption and tsunami in January 2022. With COVID-19 cases skyrocketing from just two cases in February to over 2,530 by March 17, 2022, this initiative supports relief efforts in affected communities. The rapid molecular tests provide PCR-quality results in 30 minutes and are designed for easy use without requiring additional equipment. This donation aims to ensure the health and safety of Red Cross staff and volunteers during their community outreach efforts.

Lucira Health (Nasdaq: LHDX) announces that its innovative Lucira Check-It COVID-19 test is now available for direct purchase by Canadian consumers, businesses, and healthcare providers via www.checkit.lucirahealth.ca. This test offers PCR-quality results in just 30 minutes and was the first at-home COVID-19 test authorized by Health Canada. Priced at $75 USD, it is currently offered at a discounted rate of $60 USD with a promotional code. The company aims to enhance testing convenience for safe gatherings and travel.

Lucira Health (LHDX) reported impressive fourth quarter 2021 results with net revenue of $61.1 million, marking a 300% sequential growth. Full year revenue reached $93.1 million, its first full year of commercialization. Gross profit for Q4 was approximately $12.6 million, with a gross margin of 21%. The company secured a major contract with Switch Health for over 2 million at-home COVID-19 test kits in 2022. Lucira expects Q1 2022 revenue between $80 million and $85 million and projects full year revenue exceeding $450 million.

Lucira Health, Inc. (LHDX) will announce its fourth quarter 2021 financial results on March 10, 2022. A conference call and webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and provide corporate updates. Lucira Health specializes in innovative infectious disease test kits, including the Lucira Check-It COVID-19 Test Kit, which provides results in approximately 30 minutes. The company aims to deliver lab-quality testing in a compact, user-friendly format.

Lucira Health, a medical tech company, secured a debt facility of up to $80 million with Hercules Capital and Silicon Valley Bank to enhance its financial stability and expand its commercialization efforts. The initial tranche of $30 million has been received, with additional funding contingent on achieving specific milestones. As of December 31, 2021, Lucira reported approximately $106 million in available cash. The press release also highlights the company's goals to increase product availability and operational efficiency in the rapidly evolving infectious disease testing market.

Lucira Health (LHDX) announced over two million at-home COVID-19 test kits are now available on Amazon, providing rapid results with PCR-quality accuracy. Priced at $75, the Lucira Check-It test offers results in 30 minutes, a significant improvement over traditional lab tests. With a high accuracy rate of 98% compared to lab-based PCR tests, and the ability to detect all Omicron variant genome sequences, this innovative testing solution aims to alleviate overwhelmed testing sites. The test is FDA-authorized and available without a prescription.